Last updated at 03 Jul 2024 08:10 AM
Director
DIN: 02115242
Ravindra Balwani is currently associated with 3 companies as Director. They serve as a Director at TUTIS LIFESCIENCES PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 02115242.Ravindra Balwani has previously been associated with 2 companies in roles such as Director.Ravindra Balwani is currently involved in 1 different role. Their most recent position is with AVANSDOSE PHARMATECH PRIVATE LIMITED as a Director. The first company Ravindra Balwani was appointed to as a director was TUTIS LIFESCIENCES PRIVATE LIMITED. Ravindra Balwani is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Ravindra Balwani is currently associated with 3 companies as Director. They serve as a Director at TUTIS LIFESCIENCES PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 02115242.Ravindra Balwani has previously been associated with 2 companies in roles such as Director.Ravindra Balwani is currently involved in 1 different role. Their most recent position is with AVANSDOSE PHARMATECH PRIVATE LIMITED as a Director. The first company Ravindra Balwani was appointed to as a director was TUTIS LIFESCIENCES PRIVATE LIMITED. Ravindra Balwani is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Male
India
Gain instant access to verified contact details.
Current Companies (3)
Current LLPs (0)
Past Companies (2)
4 Years 2 Years Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| TUTIS LIFESCIENCES PRIVATE LIMITED | Director | 24-Apr-2006 |
| CURACASA PHARMACEUTICALS PRIVATE LIMITED | Director | 26-May-2008 |
| AVANSDOSE PHARMATECH PRIVATE LIMITED | Director | 27-Feb-2017 |